P07 Onasemnogene abeparvovec gene-replacement therapy (GRT) for spinal muscular atrophy (SMA): from bench to bedside

Abstract

was 1 per 614. One third of these children develops DRE and half have GDD. Aetiology can be identified in 54%. Identification of aetiology is associated with DRE and GDD.